Obesity Accelerates PTPN11-Driven Leukemia via IL-17A and Suppressed GLP-1 Signaling, Dual Therapy Cuts Burden in Obese Mice

The team analyzed UK Biobank records from over 440,000 individuals and performed experiments in oncogenic PTPN11-driven mouse models of myeloid leukemia. Obesity induced chronic inflammation marked by higher IL-17A and diminished endogenous GLP-1 activity, expanding mutated hematopoietic stem cells and impairing antitumor immunity. These mechanistic links establish metabolic dysfunction as an active driver rather than a passive comorbidity.

Dual therapy with IL-17A-blocking antibodies and GLP-1 receptor agonists, already approved for autoimmune and metabolic indications, reduced leukemia burden and restored immune function specifically in obese mice. This approach simultaneously targets inflammation and metabolic reprogramming, suggesting a repurposing pathway that could address both cancer progression and obesity-related comorbidities at scale.

Rising population-level metabolic disease increases the fraction of leukemia patients who may benefit from metabolic interventions. Prior observational data link obesity to inferior AML outcomes, yet no prior interventional study had demonstrated a tractable mechanism or existing-drug combination capable of interrupting it.

Planned clinical evaluation will test safety and efficacy of the combination in obese patients with high-risk myeloid leukemias, with biomarker-driven selection to identify likely responders and extension to other obesity-associated malignancies.